Alto Neuroscience (ANRO) Reports Topline Results from a Phase 2b Trial of ALTO-100

Go back to Alto Neuroscience (ANRO) Reports Topline Results from a Phase 2b Trial of ALTO-100
(NYSE: ANRO) Delayed: 30.27 --0 (-0%)
Previous Close $30.27    52 Week High
Open $30.27    52 Week Low
Day High $30.27    P/E N/A 
Day Low $30.27    EPS
Volume 70